Repligen (NASDAQ:RGEN) had its price target boosted by JPMorgan Chase & Co. from $60.00 to $70.00 in a report published on Friday. The firm currently has an overweight rating on the biotechnology company’s stock.
Other equities analysts have also issued research reports about the stock. Stephens increased their target price on shares of Repligen from $50.00 to $55.00 and gave the stock an average rating in a research report on Tuesday, July 10th. BidaskClub lowered shares of Repligen from a strong-buy rating to a buy rating in a research report on Tuesday, July 31st. Citigroup increased their target price on shares of Repligen from $45.00 to $56.00 and gave the stock a buy rating in a research report on Friday, July 20th. Zacks Investment Research upgraded shares of Repligen from a hold rating to a buy rating and set a $62.00 target price for the company in a research report on Thursday, October 4th. Finally, Janney Montgomery Scott reiterated a buy rating on shares of Repligen in a research report on Thursday, October 4th. Three analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average target price of $57.33.
RGEN opened at $67.29 on Friday. The stock has a market cap of $2.90 billion, a P/E ratio of 97.52, a P/E/G ratio of 5.22 and a beta of 0.74. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $68.12.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $49.53 million during the quarter, compared to analyst estimates of $46.69 million. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The company’s quarterly revenue was up 35.4% on a year-over-year basis. During the same quarter last year, the business earned $0.15 earnings per share. On average, equities analysts forecast that Repligen will post 0.73 EPS for the current year.
In other news, CEO Anthony Hunt sold 27,566 shares of the stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $57.71, for a total value of $1,590,833.86. Following the sale, the chief executive officer now directly owns 255,017 shares of the company’s stock, valued at $14,717,031.07. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Thomas F. Ryan, Jr. sold 2,366 shares of the stock in a transaction dated Wednesday, August 22nd. The stock was sold at an average price of $51.44, for a total transaction of $121,707.04. Following the completion of the sale, the director now directly owns 4,988 shares in the company, valued at $256,582.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,742 shares of company stock worth $3,068,068. Insiders own 1.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in RGEN. BlackRock Inc. raised its stake in Repligen by 9.1% in the second quarter. BlackRock Inc. now owns 5,851,161 shares of the biotechnology company’s stock valued at $275,239,000 after purchasing an additional 485,777 shares in the last quarter. OppenheimerFunds Inc. raised its stake in Repligen by 7.4% in the second quarter. OppenheimerFunds Inc. now owns 2,135,929 shares of the biotechnology company’s stock valued at $100,473,000 after purchasing an additional 146,290 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in Repligen by 13.4% in the third quarter. Conestoga Capital Advisors LLC now owns 1,941,212 shares of the biotechnology company’s stock valued at $107,660,000 after purchasing an additional 230,080 shares in the last quarter. Macquarie Group Ltd. raised its stake in Repligen by 12.3% in the second quarter. Macquarie Group Ltd. now owns 1,107,691 shares of the biotechnology company’s stock valued at $52,106,000 after purchasing an additional 121,157 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Repligen by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,016,820 shares of the biotechnology company’s stock valued at $47,831,000 after purchasing an additional 3,489 shares in the last quarter. 93.08% of the stock is currently owned by hedge funds and other institutional investors.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.